According to the current analysis of Emergen Research, the global Diabetic Ketoacidosis Market was valued at USD 1297.3 million in 2019 and is expected to reach USD 1973.6 million by 2027, at a CAGR of 6.2%.
According to the current analysis of Emergen Research, the global Diabetic Ketoacidosis Market was valued at USD 1297.3 million in 2019 and is expected to reach USD 1973.6 million by 2027, at a CAGR of 6.2%. The rising prevalence of diabetes is expected to be a key driver for the growth of the diabetic ketoacidosis market. According to a report by the International Diabetes Federation, around 463 million adults were suffering from diabetes in 2019, and the number is expected to rise to 700 million by 2045. Diabetic ketoacidosis is a common complication associated with diabetes, and the rising prevalence of the disease is expected to fuel the demand for diabetic ketoacidosis treatments. Furthermore, the increasing awareness about the disease and the availability of effective treatments are expected to drive market growth over the forecast period.
Diabetic ketoacidosis (DKA) is a potentially life-threatening complication that can occur in people with diabetes mellitus. It happens when the body starts to produce high levels of blood acids called ketones. This can happen when there is not enough insulin in the body. Insulin is a hormone that helps to control blood sugar levels. DKA can occur in anyone with diabetes, but it is most common in people with type 1 diabetes. It usually happens when people are first diagnosed with diabetes or during times of illness or stress. Symptoms of DKA include nausea, vomiting, abdominal pain, and confusion. If left untreated, DKA can lead to coma or death.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/73
Significant R&D activities are being undertaken by market players to develop novel drugs for the treatment of diabetic ketoacidosis. For instance, in July 2018, AstraZeneca announced that it had completed the first phase III clinical trial (NCT03083490) on its investigational new drug saroglitazar for the treatment of diabetic ketoacidosis.
Key Highlights from the Report
- The diabetic ketoacidosis market is segmented by type into Type 1 diabetes, Type 2 diabetes, and gestational diabetes. Type 1 diabetes is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to the rising prevalence of diabetes and increasing awareness about the early diagnosis and treatment of the disease.
- The global diabetic ketoacidosis market is segmented by treatment into insulin therapy, medical nutrition therapy, and others. Insulin therapy is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to the high efficacy of insulin therapy in the treatment of diabetic ketoacidosis.
- The Beta-Hydroxybutyrate (BHB) assay segment is expected to register the fastest revenue CAGR during the forecast period due to the large number of ongoing clinical trials to study the efficacy and safety of BHB.
- The hospitals segment is expected to register the fastest revenue CAGR during the forecast period due to increasing awareness about DKA, rising number of diabetic patients, and growing preference for early diagnosis and treatment.
- The Insulin Therapy segment is expected to register the fastest revenue CAGR during the forecast period due to the increasing prevalence of diabetes and the growing awareness about the early treatment of diabetes.
- Availability of research funds from private as well as public sources, increase in diabetic population base, and advancement in technology are the major factors driving market growth. However, stringent government regulations associated with product approval and lack of awareness about diabetes are restraining market growth.
- The North American region is expected to hold the largest share of the global diabetic ketoacidosis market in 2019. The large share of this region can be attributed to a well-established healthcare system, the high prevalence of diabetes, availability of reimbursement policies, and a large number of key players operating in this region.
- Key market players operating in the global market for diabetes ketoacidosis include, Biocon, Merck, Novo Nordisk, Bristol-Myers Squibb, AstraZeneca, Sanofi, Pfizer, Eli Lilly and Company, Tonghua Dongbao Pharmaceutical, Wockhardt, GlaxoSmithKline, Oramed Pharmaceuticals and Adocia among other companies.
Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/diabetic-ketoacidosis-market
For the purpose of this study, Emergen Research has segmented Diabetic Ketoacidosis Market on the basis of treatment type, end use and region:
Treatment Type Outlook (Revenue in Million USD; 2017–2027)
- Fluid Replacement
- Electrolyte Replacement
- Insulin Therapy
- Intermediate-Acting Insulin
- Long-Acting Insulin
End Use Outlook (Revenue in Million USD; 2017–2027)
- Hospitals
- Ambulatory Care Centre
- Specialty Clinics
Regional Outlook (Revenue in Million USD; 2017–2027)
- North America
- U.S
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of the Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Latin America
- Brazil
Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/73
Explore More Reports Emergen Research:
Construction Equipment Rental Market
Quantum Computing for Enterprise Market
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trend’s existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Emergen Research Media Citations: https://www.emergenresearch.com/media-citations
Visit for More Insights: https://www.emergenresearch.com/insights
Explore Our Custom Intelligence services | Growth Consulting Services
Press Release Available @ https://www.emergenresearch.com/press-release/global-diabetic-ketoacidosis-market